ProQR Therapeutics NV PRQR.OQ PRQR.O is expected to show a fall in quarterly revenue when it reports results on March 11 (estimated) for the period ending December 31 2025
The Leiden Zuid-holland-based company is expected to report a 11.6% decrease in revenue to €3.808 million from €4.31 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.11 | -0.10 | -0.10 | Met | 2.9 |
Jun. 30 2025 | -0.09 | -0.08 | -0.12 | Missed | -46.4 |
Mar. 31 2025 | -0.11 | -0.09 | -0.10 | Missed | -8.1 |
Dec. 31 2024 | -0.11 | -0.09 | -0.09 | Met | -1.7 |
Sep. 30 2024 | -0.10 | -0.11 | -0.10 | Beat | 5.2 |
Jun. 30 2024 | -0.11 | -0.12 | -0.03 | Beat | 75.9 |
Mar. 31 2024 | -0.12 | -0.11 | -0.09 | Beat | 17.8 |
Dec. 31 2023 | -0.10 | 0.01 | -0.07 | Missed | -745.2 |
This summary was machine generated March 9 at 12:18 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments